“ The one problem with this will be the FDA. Even when they understand leronlimab is immunomodulatory they will be reluctant to approve AAV leronlimab for diseases where a limited timeline of doses will suffice.”

I’m also concerned about this. Hopeful but concerned

I suspect full RO would be ideal. That may cause some diarrhea issues. (The body flushing excess foreign protein).

As we saw in Mash/Nash different doses worked better or less (allowing all of the possible phenotypes). So from the FDAs perspective which dose is equivalent to Long Acting Leronlimab, at least in terms of RO.

And should issues arise other than diarrhea, can LA LL be reversed.

Just stuff I wonder about. I remain bullish, for both LL, and LA LL.